Sexual Desire Disorder (HSDD) in women is now technically called Female Sexual Interest/Arousal Disorder. Symptoms, which need to be present for 6 months, include nonexistent or minimal interest in sexual activity, lack of sexual thoughts/fantasies, absence of pleasure and difficulty feeling sensations during sexual contact. Additionally, these symptoms need to cause considerable distress.
For some of our patients at Maze, this condition has been ongoing from the very beginning. For others, there has been a steady decline, and there are some women for whom a light switch suddenly turned off one day.
There are treatments available and the FDA recently approved Vyleesi (bremelanotide) set to launch September 2019. Vyleesi is an injectable used 45 minutes before expected sexual activity and is not a daily medication. What excites me about Vyleesi is that it widens our options of treatment. At Maze, we are all about possibilities and enhancing treatment alternatives for women.